The studied model, referred to as the in silico EGFR+ (Epidermal Growth Factor Receptor) Lung Adenocarcinoma (ISELA) model, relies on a mechanistic representation of tumor evolution, from specific mutations to tumor size evolution. This evidence concerns the gene EGFR and lung adenocarcinoma.